Thomas D. Willis

ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA.

SpinX designs and develops products which exploit its innovative adaptive microfluidics technology. The firm's platform offers a fully integrated solution which drastically reduces manual work, while avoiding complex and costly robotics, and can be used in a wide variety of applications, from drug discovery to consumer diagnostics. The reduced consumption of samples, reagents and other consumables enables increased throughput and results in significant cost savings. Additionally, the platform enables sophisticated interleaved liquid handling and detection steps not possible with other systems. SpinX is an international, multidisciplinary - but highly focused - team with world-class competences in microfludics, opto-electronics, molecular biology, biochemistry and software. The founders of SpinX Technologies, Bart Van de Vyver, Ph.D and Piero Zucchelli, Ph.D., worked together for 10 years on various research projects at CERN, the European Organization for Nuclear Research. They have conducted leading-edge academic research in particle physics and instrumentation and managed numerous state-of-the-art research projects. The SpinX Board of Directors and Advisory Board include experts from Europe and the United States, from a variety of backgrounds and disciplines covering drug discovery, diagnostics, microfluidics and physics.

Sequenta, Inc. operates as a biotech company which discovers and develops clinical diagnostics based on immune system status. It develops molecular diagnostic assays based on a sequencing approach to the profiling of T and B cell receptor repertoires. The firm also provides sequencing-based test for minimal residual disease for leukemia and lymphoma. The company was founded by Thomas D. Willis and Malek Faham in 2007 and is headquartered in South San Francisco, CA.

Boreal Genomics, Inc. develops and markets DNA and RNA purification, enrichment, and detection equipment and tools. It provides research tools and developing diagnostic tests based on non invasive tumor profiling and monitoring of cancer. The company’s OnTarget platform performs sensitive genomic analysis of cell free DNA in plasma to detect and quantify mutations in tumor derived circulating nucleic acids. The company was founded by Andre Marziali, Jason Donald Thompson, Joel Pel and David J. Broemeling in 2007 and is headquartered in Vancouver, Canada.

Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA.

IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California.